title: [Gene-therapy for peripheral vascular diseases].
abstract: The prognosis for patients with chronic critical leg ischemic is often poor. The treatment of peripheral vascular disease, although greatly improved over recent decades by drug medication, surgical and minimally-invasive techniques, remains limited by vascular proliferative lesions and by our inability to modulate the progression of native disease. The therapeutic angiogenesis is now the most expected therapy for peripheral vascular diseases. This review explores some of concepts and methods of therapeutic angiogenesis including gene therapy using angiogenic growth factor such as VEGF and basic FGF and an implantation of bone marrow derived endothelial progenitor cells.
authors.affiliation: Department of Internal Medicine II, Kansai Medical University.
authors.forename: H
authors.initials: H
authors.lastname: Masaki
authors.forename: E
authors.initials: E
authors.lastname: Tateishi
authors.forename: H
authors.initials: H
authors.lastname: Matsubara
authors.forename: T
authors.initials: T
authors.lastname: Iwasaka
mesh_terms: D000818:Animals; D001162:Arteriosclerosis Obliterans / Q000628:therapy*; D016026:Bone Marrow Transplantation; D016228:Endothelial Growth Factors / Q000235:genetics; D004730:Endothelium, Vascular / Q000166:cytology; D016222:Fibroblast Growth Factor 2 / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D008222:Lymphokines / Q000235:genetics; D018919:Neovascularization, Physiologic; D033581:Stem Cell Transplantation; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2